Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Point-of-care testing in hemostasis.in: Kitchen S. Olson J. Preston F.E. Quality in laboratory hemostasis and thrombosis. Wiley-Blackwell, Hoboken (NJ)2009: 72-80
- Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment.Am J Clin Pathol. 2007; 128: 143-149
- Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.J Thromb Haemost. 2006; 4: 312-319
- Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease.Thromb Haemost. 2000; 84: 88-92
- Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI.J Thromb Haemost. 2008; 6: 1824-1826
- Aspirin resistance: position paper of the Working Group on Aspirin Resistance.J Thromb Haemost. 2005; 3: 1309-1311
- Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).Chest. 2008; 133: 199S-233S
- The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).Chest. 2008; 133: 299S-339S
- Aspirin dose for the prevention of cardiovascular disease: a systematic review.JAMA. 2007; 297: 2018-2024
- A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.J Am Coll Cardiol. 2003; 41: 961-965
- Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?.J Am Coll Cardiol. 2007; 49: 657-666
- Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.J Am Coll Cardiol. 2007; 49: 2312-2317
- Aspirin resistance and adverse clinical events in patients with coronary artery disease.Am J Med. 2007; 120: 631-635
- Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.Am J Cardiol. 2007; 99: 1518-1522
- Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.Eur Heart J. 2008; 29: 992-1000
- Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.Circulation. 2009; 119: 237-242
- Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity predicts Outcome) study.J Am Coll Cardiol. 2008; 52: 1128-1133
- Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study.Thromb Res. 2006; 118: 487-493
- Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.Am J Cardiol. 2006; 98: 1156-1159
- Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.Thromb Res. 2002; 108: 37-42
- Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).Blood Coagul Fibrinolysis. 2007; 18: 187-192
- Cytochrome p-450 polymorphisms and response to clopidogrel.N Engl J Med. 2009; 360: 354-362
- Genetic determinants of response to clopidogrel and cardiovascular events.N Engl J Med. 2009; 360: 363-375
- Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.JAMA. 2009; 301: 937-944
- A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.CMAJ. 2009; 180: 713-718
- Clopidogrel, genetics, and drug responsiveness.N Engl J Med. 2009; 360: 411-413
- Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment.Clin Chem. 2006; 52: 1843-1847
- International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy.Thromb Haemost. 2009; 101: 563-569
- Accuracy of capillary whole blood international normalized ratio on the CoaguChek S, CoaguChek XS, and i-STAT 1 point-of-care analyzers.Am J Clin Pathol. 2008; 130: 88-92
- Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial.Thromb Haemost. 2008; 100: 1089-1098
- Evaluation of the CoaguChek XS Plus system in a Swiss community setting.Thromb Haemost. 2009; 101: 988-990
- Comparative study of accuracy and clinical agreement of the CoaguChek XS portable device versus standard laboratory practice in unexperienced patients.Thromb Haemost. 2009; 101: 969-974
- Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.Lancet. 2006; 367: 404-411
- Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).Chest. 2008; 133: 160S-198S
- Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy.Arch Intern Med. 1993; 153: 1441-1447
- A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin.Thromb Haemost. 2000; 84: 410-412
- Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies.Thromb Haemost. 2005; 94: 1196-1202
- Influence of haematocrit on international normalised ratio (INR) differences between a whole blood point-of-care coagulation monitor and reference prothrombin time in plasma.Thromb Haemost. 2008; 100: 1181-1184
- D-dimer testing for deep venous thrombosis: a metaanalysis.Clin Chem. 2004; 50: 1136-1147
- Comparison of two rapid D-dimer assays for the exclusion of venous thromboembolism.Blood Coagul Fibrinolysis. 1998; 9: 387-388
- Diagnostic accuracy of a bedside D-dimer assay and alveolar dead-space measurement for rapid exclusion of pulmonary embolism: a multicenter study.JAMA. 2001; 285: 761-768
- Diagnostic accuracy of the Triage D-dimer test for exclusion of venous thromboembolism in outpatients.Thromb Res. 2008; 121: 735-741
- Evaluation of the Biosite Triage® quantitative whole blood D-dimer assay and comparison with the bioMerieux VIDAS® D-dimer exclusion test: validation and utility for use in the central laboratory and at the point of care.Point of Care. 2005; 4: 133-137
- Performance characteristics of the AxSYM D-dimer assay.Clin Chim Acta. 2008; 390: 148-151
Lee-Lewandrowski E, Nichols J, VanCott EM, et al. Implementation of a rapid whole blood D-dimer test in the emergency department of an urban academic medical center: impact on ED length of stay and ancillary test utilization. Am J Clin Pathol, in press.
- Diagnosis accuracy of a new challenger for thrombosis exclusion, the Stratus CS DDMR.Clin Chim Acta. 2005; 354: 181-189
- A new rapid point-of-care D-dimer enzyme-linked immunosorbent assay (Stratus CS D-dimer) for the exclusion of venous thromboembolism.Blood Coagul Fibrinolysis. 2004; 15: 435-438
- Diagnostic value of the D-dimer test in deep vein thrombosis: improved results by a new assay method and by using discriminate levels.Thromb Res. 2001; 102: 125-131
- Appropriate indications for venous duplex scanning based on D-dimer assay.Ann Vasc Surg. 2002; 16: 304-308
- Comparison of six D-dimer methods in patients suspected of deep vein thrombosis.Blood Coagul Fibrinolysis. 2003; 14: 545-550
- The usefulness of five D-dimer assays in the exclusion of deep venous thrombosis.J Thromb Haemost. 2003; 1: 976-981
- An evaluation of rapid D-dimer assays for the exclusion of deep vein thrombosis.Br J Haematol. 2005; 128: 842-848
- Results of a new rapid d-dimer assay (cardiac d-dimer) in the diagnosis of deep vein thrombosis.Thromb Res. 2001; 103: 17-23
- Sensitivity and specificity of a quantitative point of care D-dimer assay using heparinized whole blood, in patients with clinically suspected deep vein thrombosis.Thromb Haemost. 2006; 96: 79-83
- A new rapid bedside assay for quantitative testing of D-dimer (Cardiac D-Dimer) in the diagnostic work-up for deep vein thrombosis.Thromb Res. 2003; 111: 149-153
- Comparing the activated clotting times obtained from 2 point-of-care devices in patients receiving unfractionated heparin during percutaneous coronary intervention.Point of Care. 2008; 7: 30-33
- Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation.Thromb Haemost. 2009; 101: 535-540
- Activated clotting time: methods and clinical applications.Point of Care. 2005; 4: 90-94
- The risk associated with aprotinin in cardiac surgery.N Engl J Med. 2006; 354: 353-365
- Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.JAMA. 2007; 297: 471-479
Article info
Identification
Copyright
© 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
